EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
87.1%
45M of 51M shares
Institutional holders
195
33 new, 26 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $1.11M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,651,339 | 9.00% | 13G (passive) amendment | Jun 30, 2026 |
| Oak Hill Advisors, L.P. | 3,613,338 | 6.39% | 13G (passive) | Sep 30, 2024 |
| Stowers Institute for Medical Research | 2,770,448 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Dimensional Fund Advisors LP | 2,757,158 | 5.30% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 2,696,375 | 5.10% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EBS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,716,599 | 9.20% | $39.53M | +375,137 | 0.00% |
| Dimensional Fund Advisors LP | 3,076,646 | 6.00% | $25.78M | +319,488 | 0.00% |
| State Street Corp | 2,929,238 | 5.71% | $24.56M | +79,537 | 0.00% |
| American Century Companies Inc | 2,770,448 | 5.40% | $23.22M | +344,726 | 0.01% |
| Vanguard Capital Management LLC | 2,198,839 | 4.29% | $18.43M | −59,156 | 0.00% |
| Lsv Asset Management | 1,695,851 | 3.31% | $14.21K | +799,151 | 0.03% |
| Acadian Asset Management LLC | 1,344,323 | 2.62% | $11.26K | −37,301 | 0.01% |
| Geode Capital Management, LLC | 1,337,243 | 2.61% | $11.21M | +64,334 | 0.00% |
| Charles Schwab Investment Management Inc | 1,200,791 | 2.34% | $10.06M | −305,284 | 0.00% |
| Oak Hill Advisors LP | 1,113,338 | 2.17% | $9.33M | – | 1.33% |
| Millennium Management LLC | 1,072,185 | 2.09% | $8.98M | +540,184 | 0.00% |
| Ancora Advisors, LLC | 1,067,867 | 2.08% | $8.95M | +658,600 | 0.17% |
| Aqr Capital Management LLC | 1,041,151 | 2.03% | $8.72M | +51,474 | 0.00% |
| Goldman Sachs Group Inc | 1,035,421 | 2.02% | $8.68M | +223,861 | 0.00% |
| Vanguard Portfolio Management LLC | 1,029,371 | 2.01% | $8.63M | −87,907 | 0.00% |
| D. E. Shaw & Co., Inc. | 900,108 | 1.76% | $7.54M | −103,804 | 0.00% |
| Russell Investments Group, Ltd. | 859,482 | 1.68% | $7.20M | +523,584 | 0.01% |
| Federated Hermes, Inc. | 831,125 | 1.62% | $6.96M | +374,806 | 0.01% |
| Prudential Financial Inc | 805,895 | 1.57% | $6.75M | +357,080 | 0.01% |
| Prescott Group Capital Management, L.L.C. | 772,771 | 1.51% | $6.48M | – | 0.56% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 195 | 45M | 87.1% | 33 / 69 | 63 / 26 | 7M | 5M |
| Q1 2026 | 190 | 43M | 84.7% | 37 / 69 | 54 / 26 | 10M | 6M |
| Q4 2025 | 183 | 44M | 84.9% | 42 / 61 | 51 / 25 | 5M | 4M |
| Q3 2025 | 169 | 42M | 81.4% | 37 / 49 | 53 / 29 | 6M | 4M |
| Q2 2025 | 161 | 40M | 77.4% | 41 / 54 | 40 / 40 | 11M | 7M |
| Q1 2025 | 161 | 36M | 70.7% | 35 / 53 | 40 / 28 | 7M | 6M |
| Q4 2024 | 156 | 35M | 67.8% | 37 / 46 | 36 / 21 | 7M | 4M |
| Q3 2024 | 140 | 32M | 61.8% | 33 / 30 | 50 / 31 | 12M | 7M |
| Q2 2024 | 141 | 31M | 60.6% | 49 / 35 | 36 / 29 | 7M | 15M |
| Q1 2024 | 121 | 39M | 75.7% | 20 / 30 | 46 / 33 | 10M | 13M |
| Q4 2023 | 134 | 42M | 82.3% | 19 / 47 | 43 / 46 | 10M | 9M |
| Q3 2023 | 162 | 41M | 80.3% | 26 / 47 | 54 / 46 | 10M | 15M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EBS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Avantis U.S. Small Cap Value ETF | 2,270,234 | 4.43% | $20.70M | 0.08% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,706,238 | 3.33% | $14.30M | 0.13% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,554,116 | 3.03% | $13.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,382,590 | 2.70% | $11.59M | 0.01% | Jun 30, 2026 |
| Schwab Fundamental U.S. Small Company ETF | 757,640 | 1.48% | $6.91M | 0.08% | May 31, 2026 |
| U.S. Small Cap Value Portfolio | 705,560 | 1.38% | $5.09M | 0.03% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 630,315 | 1.23% | $4.55M | 0.20% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 592,784 | 1.16% | $4.97M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 569,090 | 1.11% | $4.11M | 0.01% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 528,566 | 1.03% | $4.43M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 502,380 | 0.98% | $4.21M | 0.03% | Jun 30, 2026 |
| U.S. Targeted Value Portfolio | 443,468 | 0.86% | $3.20M | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Targeted Value ETF | 374,907 | 0.73% | $2.71M | 0.02% | Jul 31, 2026 |
| PIMCO RAE US Small Fund | 350,629 | 0.68% | $2.94M | 0.08% | Jun 30, 2026 |
| iShares Biotechnology ETF | 343,571 | 0.67% | $2.88M | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Zsolt Harsanyi | Chairman, Director | 149,076 | 0.29% | May 4, 2026 |
| Joseph C. Papa | President and CEO, Director | 493,153 | 0.96% | May 1, 2026 |
| Stephanie Duatschek | EVP, CGO | 197,416 | 0.39% | Aug 12, 2026 |
| Paul Anthony Williams | SVP, Products Business | 159,098 | 0.31% | Jul 2, 2026 |
| William Hartzel | SVP, Bioservices | 185,558 | 0.36% | Jun 10, 2026 |
| Coleen Glessner | EVP, Quality & Ethics, and CPL | 202,201 | 0.39% | Jun 10, 2026 |
| Richard S. Lindahl | EVP, Chief Financial Officer | 374,083 | 0.73% | Jun 10, 2026 |
| Jessica Perl | SVP, General Counsel, Corp Sec | 165,286 | 0.32% | May 1, 2026 |
| Simon C. Lowry | SVP, R&D, CMO | 177,914 | 0.35% | May 1, 2026 |
| John D. Fowler Jr | Director | 30,350 | 0.06% | May 4, 2026 |
| Marvin L. White | Director | 113,839 | 0.22% | May 4, 2026 |
| Ronald Richard | Director | 123,761 | 0.24% | May 4, 2026 |
| Keith Katkin | Director | 96,294 | 0.19% | May 4, 2026 |
| Kathryn C. Zoon | Director | 80,998 | 0.16% | May 4, 2026 |
| Neal Franklin Fowler | Director | 160,847 | 0.31% | May 4, 2026 |
| Sujata Tyagi Dayal | Director | 101,543 | 0.20% | May 4, 2026 |
| Donald W. DeGolyer | Director | 130,675 | 0.25% | May 4, 2026 |
| Louis W. Sullivan | Director | 139,098 | 0.27% | May 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Anthony Williams SVP, Products Business | Jul 1, 2026 | Sale(10b5-1 plan) | −3,000 | $8.40 | $25.20K | 159,098 |
| Paul Anthony Williams SVP, Products Business | Jun 8, 2026 | Tax withholding | −694 | $8.00 | $5.55K | 162,098 |
| William Hartzel SVP, Bioservices | Jun 8, 2026 | Tax withholding | −1,741 | $8.00 | $13.93K | 185,558 |
| Richard S. Lindahl EVP, Chief Financial Officer | Jun 8, 2026 | Tax withholding | −3,964 | $8.00 | $31.71K | 374,083 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Jun 8, 2026 | Tax withholding | −2,018 | $8.00 | $16.14K | 202,201 |
| Sujata Tyagi Dayal Director | May 1, 2026 | Sale(10b5-1 plan) | −12,781 | $8.36 | $106.85K | 101,543 |
| Sujata Tyagi Dayal Director | May 1, 2026 | Sale(10b5-1 plan) | −980 | $8.94 | $8.76K | 100,563 |
| Donald W. DeGolyer Director | May 1, 2026 | Sale(10b5-1 plan) | −14,527 | $8.36 | $121.45K | 130,675 |
| Donald W. DeGolyer Director | May 1, 2026 | Sale(10b5-1 plan) | −954 | $8.96 | $8.55K | 129,721 |
| Kathryn C. Zoon Director | May 1, 2026 | Sale(10b5-1 plan) | −16,145 | $8.36 | $134.97K | 80,998 |
| Kathryn C. Zoon Director | May 1, 2026 | Sale(10b5-1 plan) | −1,057 | $8.97 | $9.48K | 79,941 |
| Sujata Tyagi Dayal Director | Apr 30, 2026 | Award | +25,344 | – | – | 114,324 |
| Keith Katkin Director | Apr 30, 2026 | Sale(10b5-1 plan) | −15,481 | $8.28 | $128.18K | 96,294 |
| Keith Katkin Director | Apr 30, 2026 | Award | +25,344 | – | – | 111,775 |
| Ronald Richard Director | Apr 30, 2026 | Award | +25,344 | – | – | 123,761 |
| Neal Franklin Fowler Director | Apr 30, 2026 | Award | +25,344 | – | – | 160,847 |
| Donald W. DeGolyer Director | Apr 30, 2026 | Award | +25,344 | – | – | 145,202 |
| Marvin L. White Director | Apr 30, 2026 | Award | +25,344 | – | – | 113,839 |
| Kathryn C. Zoon Director | Apr 30, 2026 | Award | +25,344 | – | – | 97,143 |
| John D. Fowler Jr Director | Apr 30, 2026 | Award | +25,344 | – | – | 30,350 |
| Zsolt Harsanyi Chairman, Director | Apr 30, 2026 | Award | +25,344 | – | – | 149,076 |
| Paul Anthony Williams SVP, Products Business | Apr 29, 2026 | Award | +100,111 | – | – | 162,792 |
| Joseph C. Papa President and CEO, Director | Apr 29, 2026 | Award | +187,708 | – | – | 493,153 |
| Jessica Perl SVP, General Counsel, Corp Sec | Apr 29, 2026 | Award | +104,282 | – | – | 165,286 |
| William Hartzel SVP, Bioservices | Apr 29, 2026 | Award | +100,111 | – | – | 187,299 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Apr 29, 2026 | Award | +100,111 | – | – | 204,219 |
| Richard S. Lindahl EVP, Chief Financial Officer | Apr 29, 2026 | Award | +162,680 | – | – | 378,047 |
| Simon C. Lowry SVP, R&D, CMO | Apr 29, 2026 | Award | +100,111 | – | – | 177,914 |
| Paul Anthony Williams SVP, Products Business | Apr 1, 2026 | Sale(10b5-1 plan) | −4,000 | $8.44 | $33.76K | 62,681 |
| Paul Anthony Williams SVP, Products Business | Mar 5, 2026 | Tax withholding | −9,397 | $8.44 | $79.31K | 66,681 |
| Jessica Perl SVP, General Counsel, Corp Sec | Mar 5, 2026 | Tax withholding | −6,465 | $8.44 | $54.56K | 61,004 |
| Joseph C. Papa President and CEO, Director | Mar 5, 2026 | Tax withholding | −37,055 | $8.44 | $312.74K | 305,445 |
| William Hartzel SVP, Bioservices | Mar 5, 2026 | Tax withholding | −9,493 | $8.44 | $80.12K | 87,188 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Mar 5, 2026 | Tax withholding | −8,199 | $8.44 | $69.20K | 104,108 |
| Richard S. Lindahl EVP, Chief Financial Officer | Mar 5, 2026 | Tax withholding | −23,650 | $8.44 | $199.61K | 215,367 |
| Simon C. Lowry SVP, R&D, CMO | Mar 5, 2026 | Tax withholding | −10,636 | $8.44 | $89.77K | 77,803 |
| John D. Fowler Jr Director | Mar 3, 2026 | Award | +5,006 | $8.99 | $45.00K | 5,006 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Mar 1, 2026 | Tax withholding | −313 | $8.15 | $2.55K | 112,307 |
| Paul Anthony Williams SVP, Products Business | Mar 1, 2026 | Tax withholding | −116 | $8.15 | $945 | 76,078 |
| Richard S. Lindahl EVP, Chief Financial Officer | Mar 1, 2026 | Tax withholding | −683 | $8.15 | $5.57K | 239,017 |
| Jessica Perl SVP, General Counsel, Corp Sec | Feb 9, 2026 | Tax withholding | −918 | $11.03 | $10.13K | 67,469 |
| William Hartzel SVP, Bioservices | Feb 6, 2026 | Tax withholding | −630 | $10.92 | $6.88K | 96,681 |
| William Hartzel SVP, Bioservices | Feb 6, 2026 | Returned to company | −5,771 | $10.92 | $63.02K | 97,311 |
| Paul Anthony Williams SVP, Products Business | Feb 6, 2026 | Tax withholding | −1,022 | $10.92 | $11.16K | 76,194 |
| Paul Anthony Williams SVP, Products Business | Feb 6, 2026 | Returned to company | −8,655 | $10.92 | $94.51K | 77,216 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Feb 6, 2026 | Tax withholding | −2,852 | $10.92 | $31.14K | 112,620 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Feb 6, 2026 | Returned to company | −28,847 | $10.92 | $315.01K | 115,472 |
| Richard S. Lindahl EVP, Chief Financial Officer | Feb 6, 2026 | Tax withholding | −5,642 | $10.92 | $61.61K | 239,700 |
| Richard S. Lindahl EVP, Chief Financial Officer | Feb 6, 2026 | Returned to company | −46,155 | $10.92 | $504.01K | 245,342 |
| Simon C. Lowry SVP, R&D, CMO | Dec 14, 2025 | Tax withholding | −3,543 | $11.41 | $40.43K | 88,439 |
| Ronald Richard Director | Dec 5, 2025 | Sale | −7,100 | $12.11 | $85.98K | 98,417 |
| Ronald Richard Director | Dec 5, 2025 | Option exercise | +25,748 | $5.02 | $129.25K | 124,165 |
| Ronald Richard Director | Dec 5, 2025 | Tax withholding | −10,864 | $11.90 | $129.28K | 113,301 |
| Ronald Richard Director | Dec 5, 2025 | Sale | −14,884 | $11.90 | $177.12K | 98,417 |
| William Hartzel SVP, Bioservices | Nov 11, 2025 | Tax withholding | −610 | $10.88 | $6.64K | 103,082 |
| Donald W. DeGolyer Director | Nov 10, 2025 | Sale(10b5-1 plan) | −17,801 | $10.54 | $187.62K | 119,858 |
| Sujata Tyagi Dayal Director | Nov 7, 2025 | Sale(10b5-1 plan) | −8,552 | $10.00 | $85.52K | 88,980 |
| Richard S. Lindahl EVP, Chief Financial Officer | Oct 15, 2025 | Tax withholding | −4,995 | $9.60 | $47.95K | 291,497 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Oct 7, 2025 | Sale(10b5-1 plan) | −30,608 | $10.00 | $306.08K | 144,319 |
| Kathryn C. Zoon Director | Aug 15, 2025 | Sale(10b5-1 plan) | −7,086 | $8.87 | $62.85K | 71,799 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Degolyer Donald Director | Oct 7, 2026 | 17,800 | $126.12K | Oct 7, 2026 | Restricted Stock |
| Williams Paul Officer | Oct 1, 2026 | 3,000 | $19.59K | Oct 1, 2026 | Restricted Stock |
| Williams Paul Officer | Jul 1, 2026 | 3,000 | $25.21K | Jul 1, 2026 | Restricted Stock |
| Zoon Kathryn Director | May 1, 2026 | 17,202 | $144.49K | May 1, 2026 | Restricted Stock |
| Tyagi Dayal Sujata Director | May 1, 2026 | 13,761 | $115.61K | May 1, 2026 | Restricted Stock |
| Degolyer Donald Director | May 1, 2026 | 15,481 | $130.06K | May 1, 2026 | Restricted Stock |
| Katkin Keith Director | Apr 30, 2026 | 15,481 | $128.14K | Apr 30, 2026 | Restricted Stock |
| Williams Paul Officer | Apr 1, 2026 | 4,000 | $33.78K | Apr 1, 2026 | Restricted Stock |
| W. Sullivan Louis Director | Jan 7, 2026 | 25,748 | $360.14K | Jan 7, 2026 | Stock Option Exercise |
| W. Sullivan Louis Director | Dec 22, 2025 | 104,695 | $1.34M | Dec 22, 2025 | Restricted Stock |
| Richard Ronald Director | Dec 5, 2025 | 32,848 | $392.33K | Dec 5, 2025 | Restricted Stock |
| Degolyer Donald Director | Nov 10, 2025 | 17,801 | $187.54K | Nov 10, 2025 | Restricted Stock |
| Tyagi Dayal Sujata Director | Nov 7, 2025 | 8,552 | $85.52K | Nov 7, 2025 | Restricted Stock |
| Glessner Coleen Officer | Oct 7, 2025 | 30,608 | $306.08K | Oct 7, 2025 | Restricted Stock |
| Zoon Kathryn Director | Aug 15, 2025 | 7,086 | $62.85K | Aug 15, 2025 | Restricted Stock |